BrainSonix Corporation
BrainSonix Corporation is a private, clinical-stage medical device company that develops and manufactures the BX Pulsar 1002 LIFUP system and accessories for non-invasive brain neuromodulation, currently selling to research hospitals and academic centers under FDA IDE clinical trials.
- Company typePrivate
- Founded2003
- HeadquartersSherman Oaks, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What BrainSonix Corporation does
BrainSonix Corporation is a privately held, clinical-stage medical device company founded in 2003 in Los Angeles, California, by Dr. Alexander (Sasha) Bystritsky, the inventor of Low-Intensity Focused Ultrasound Pulsation (LIFUP) for human brain modulation and a UCLA Professor Emeritus. The company designs and manufactures the BX Pulsar 1002 neuromodulation system together with custom 650 kHz spherically curved transducers, gel pads, and a quality assurance tester. Its core technology uses low-intensity, pulsed focused ultrasound to mechanically modulate mechanosensitive ion channels and synaptic activity in millimeter-scale focal zones deep within the brain, achieving a non-thermal mechanism that contrasts with high-intensity focused ultrasound ablation. The platform is MR safe and MRI compatible and is paired with proprietary dosimetry software plus neuronavigation integration for real-time targeting under fMRI guidance.
The company's go-to-market is currently oriented to research and clinical-trial use under multiple FDA Investigational Device Exemptions (IDE), covering indications including epilepsy, disorders of consciousness, amygdala-driven conditions, depression, OCD, anxiety, PTSD, Parkinson's, Alzheimer's, and chronic pain. Customers are leading academic medical centers and research hospitals such as UCLA, Stanford, Harvard/Massachusetts General Hospital, and NYU, where the system is used both as an investigational therapy and as a research tool for circuit mapping. Pricing is not publicly disclosed and is described as negotiated on a per-institution basis, with no commercial revenue, ARR, or institutional funding rounds disclosed in available materials. Revenue mechanics are oriented around hardware sales of the BX Pulsar 1002 system and consumable/replacement transducers and gel pads, supplemented by the quality assurance tester. BrainSonix holds granted patents covering its transducer and housing design, the LIFUP device architecture, and two method-of-use patents.
Operationally, BrainSonix runs a lean 1-10 person organization supported by an externalized commercialization model: a strategic partnership with Soterix Medical covers development, manufacturing, and global distribution, allowing the company to access neuromodulation sales infrastructure without building it in-house. Senior leadership beyond the founder includes a Chief Legal Officer with prior public-company experience (RingCentral), a Head of Compliance and Engineering Operations with prior Class II/III medical device experience at Abbott, Medtronic, and Epredia, a Head of Customer Relations, and a Medical Advisory Board chaired by senior KOLs from Stanford (former APA president), NYU, and Harvard/MGH. The company is designed to comply with IEC 60601, ISO 13485, and EU MDR frameworks as it advances toward potential commercialization beyond IDE research use.
BrainSonix Corporation firmographics
Firmographics- Name
- BrainSonix Corporation
- Legal name
- Brain Sonix Corporation
- Website
- https://brainsonix.com
- Company type
- Private
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- BrainSonix Corporation is a private, clinical-stage medical device company that develops and manufactures the BX Pulsar 1002 LIFUP system and accessories for non-invasive brain neuromodulation, currently selling to research hospitals and academic centers under FDA IDE clinical trials.
- Ownership category
- akta.pro rank
BrainSonix Corporation industry classification
Industry- Product category
- Focused Ultrasound Neuromodulation Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)
- akta.pro secondary industry
- Electrophysiology Mapping & Ablation Systems (HLAHAFAD)
Keywords
Where BrainSonix Corporation is headquartered
LocationHeadquarters
- HQ city
- Sherman Oaks
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
BrainSonix Corporation business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Medical Device Sales: BrainSonix develops and manufactures LIFUP medical devices for clinical and research use. As an FDA-regulated medical device company operating under IDE approvals, revenue will be generated through sale of the BX Pulsar system and related hardware to research institutions and healthcare facilities.
- Transducers and Accessories: Sale of specialized transducers and gel pads as consumable/replacement components for the LIFUP system.
- Quality Assurance Tester: Sale of quality assurance testing equipment for validating transducer performance.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
BrainSonix Corporation product offering
Product offeringCore offering
BrainSonix develops and manufactures the BX Pulsar 1002, a proprietary Low-Intensity Focused Ultrasound Pulsation (LIFUP) medical device for non-invasive brain neuromodulation that targets deep brain structures with millimeter precision via custom 650 kHz transducers. The company sells this system along with replacement transducers, acoustic-coupling gel pads, and a quality assurance tester to research hospitals, university medical centers, and clinical research institutions conducting FDA IDE-authorized neuromodulation studies.
Product overview
BrainSonix Corporation offers a proprietary Low-Intensity Focused Ultrasound Pulsation (LIFUP) platform for non-invasive brain neuromodulation. The core product portfolio centers on the BX Pulsar 1002 medical device, supported by custom transducers operating at 650 kHz, gel pads for acoustic coupling, and quality assurance testing tools. The platform integrates proprietary dosimetry software and supports neuronavigation integration with fMRI for precise targeting. The company also provides LIFUP technology for research and clinical applications targeting neurological, psychiatric, and chronic medical disorders.
Differentiator
Problem solved
Functional benefit
Brands
- BX Pulsar 1002: Focused ultrasound pulsation device for neuromodulation
- LIFUP
- Quality Assurance Tester
- Transducers
- Gel Pads
Products and services
- BX Pulsar 1002 Primary BrainSonix medical device platform implementing proprietary Low-Intensity Focused Ultrasound Pulsation (LIFUP) technology for safe, targeted, non-invasive neuromodulation of the brain. Designed for clinical research and investigational use under FDA IDE approvals by research hospitals, university medical centers, and clinical research institutions.
- Transducers Custom BrainSonix transducers with spherical curvature that operate at approximately 650 kHz fundamental frequency to concentrate ultrasound waves into a millimeter-scale focal zone within the brain. Sold as components/accessories for the BX Pulsar 1002 LIFUP system.
- Gel Pads Coupling gel pads used between the transducer and scalp to facilitate optimal ultrasound transmission through the skull. Sold as consumable/replacement accessories for the BX Pulsar 1002 LIFUP system.
- Quality Assurance Tester Quality assurance testing tool for verifying and validating the proper functioning of the BrainSonix LIFUP system and its transducers before clinical or research use.
Quantifiable outcome
- 40-60% of patients do not achieve full relief from standard medications for depression, epilepsy, and other conditions, creating significant market need for neuromodulation alternatives.
- +2 more outcomes
Companies that use BrainSonix Corporation
Customer profileSegments2 records
Ideal customer profiles2 records
BrainSonix Corporation technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
BrainSonix Corporation partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Soterix MedicalcoreBrainSonix is a collaborative partner with Soterix Medical for the Development, Manufacturing and Distribution of BrainSonix systems and technology. This partnership enables BrainSonix to leverage Soterix Medical's established infrastructure for bringing the LIFUP technology to market, combining development expertise with manufacturing and distribution capabilities.
Scale indicators2 records
Recent moves6 records
Expansion highlights5 records
BrainSonix Corporation competitors and assessment
Company assessmentEmerging players
- Neuralink: High-profile developer of invasive brain-computer interface technology. Adjacent competitor in CNS-interface innovation, illustrative of well-funded pressure on the broader neuromodulation/brain-intervention category.
- Soterix Medical: Developer of non-invasive brain stimulation technologies including tDCS and HD-tDCS, and BrainSonix's strategic partner for development, manufacturing, and distribution. Deeply intertwined peer given the commercial partnership.
- electroCore: Developer of non-invasive vagus nerve stimulation (nVNS) for headache and neurological conditions. Comparable non-invasive, non-implant neuromodulation modality targeting adjacent CNS indications.
Direct peers
- BrainsWay: Commercial-stage developer of Deep TMS systems for depression, OCD, and other psychiatric disorders. Closest direct competitor in non-invasive brain stimulation with overlapping clinical indications.
- Neuronetics: Commercial-stage NeuroStar TMS system focused on major depressive disorder. Direct competitor in the non-invasive neuromodulation space with established FDA clearance and reimbursement.
- InSightec: Focused ultrasound developer with FDA-cleared Exablate Neuro system for tremor and Parkinson's. Closest analog by underlying energy modality (focused ultrasound for brain intervention), though at higher intensities.
- Magstim: Long-established manufacturer of transcranial magnetic stimulation systems for research and clinical use. Direct competitor in non-invasive brain stimulation with overlapping neuroscience research customer base.
Broad incumbents
- Medtronic: Established manufacturer of Deep Brain Stimulation (DBS) systems for Parkinson's, dystonia, and OCD. Incumbent in the implantable neuromodulation category LIFUP positions against as a non-invasive alternative.
- Abbott: DBS manufacturer via its St. Jude Medical portfolio, with FDA-approved systems for movement disorders. Incumbent neuromodulation player positioned against the same patient populations BrainSonix targets.
- Boston Scientific: DBS and spinal cord stimulation manufacturer. Large incumbent in implantable neuromodulation with overlapping therapeutic indications in Parkinson's and chronic pain.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
BrainSonix Corporation social profiles
Digital presenceBrainSonix Corporation compliance and trust
Trust signalCompliance3 records
BrainSonix Corporation financial estimates
Financial estimateRevenue estimate
Valuation estimate
BrainSonix Corporation leadership team
Management profileNumber of profiles
Profiles7 records
BrainSonix Corporation funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BrainSonix Corporation M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BrainSonix Corporation
What does BrainSonix Corporation do?
BrainSonix develops and manufactures the BX Pulsar 1002, a proprietary Low-Intensity Focused Ultrasound Pulsation (LIFUP) medical device for non-invasive brain neuromodulation that targets deep brain structures with millimeter precision via custom 650 kHz transducers. The company sells this system along with replacement transducers, acoustic-coupling gel pads, and a quality assurance tester to research hospitals, university medical centers, and clinical research institutions conducting FDA IDE-authorized neuromodulation studies.
Is BrainSonix Corporation a public or private company?
BrainSonix Corporation is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was BrainSonix Corporation founded?
BrainSonix Corporation was founded in 2003. It employs 1 to 10 people.
Where is BrainSonix Corporation based?
BrainSonix Corporation is headquartered in Sherman Oaks, United States, in the North America region.
How does BrainSonix Corporation make money?
Three revenue lines are on record. Medical Device Sales are the primary driver. The others are transducers and Accessories and quality Assurance Tester.
Who are BrainSonix Corporation's main competitors?
Emerging players on record are Neuralink, Soterix Medical and electroCore. Direct peers are BrainsWay, Neuronetics, InSightec and Magstim. Broad incumbents are Medtronic, Abbott and Boston Scientific.
Does BrainSonix Corporation have an API?
No public API is recorded for BrainSonix Corporation.
What industry is BrainSonix Corporation in?
BrainSonix Corporation's product category is Focused Ultrasound Neuromodulation Medical Devices. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS), with a secondary code of HLAHAFAD, Electrophysiology Mapping & Ablation Systems. Its NAICS code is 334510 and its SIC code is 3845.